Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection

INTRODUCTION: Effective treatments for recurrent Clostridioides difficile infection (rCDI) are urgently needed. RBX2660 is an investigational microbiota-based live biotherapeutic to reduce CDI recurrence following standard-of-care antibiotic treatment in individuals with rCDI. Here we report the fin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubberke, Erik R., Orenstein, Robert, Khanna, Sahil, Guthmueller, Beth, Lee, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925615/
https://www.ncbi.nlm.nih.gov/pubmed/36544075
http://dx.doi.org/10.1007/s40121-022-00744-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925615/
https://www.ncbi.nlm.nih.gov/pubmed/36544075
http://dx.doi.org/10.1007/s40121-022-00744-3

Ejemplares similares